Table 1.
Baseline characteristics
| Control (10) | Intervention (21) | ||
|---|---|---|---|
| Age | Mean (SD) | 64.2 (8.9) | 59.1 (11) |
| Race | White, % (n) | 100.0 (10) | 90.5 (19) |
| Black, % (n) | 0 | 4.8 (1) | |
| No answer, % (n) | 0 | 4.8 (1) | |
| Ethnicity | Not Hispanic/Latino, % (n) | 100.0 (10) | 95.2 (20) |
| No answer, % (n) | 0 | 4.8 (1) | |
| Marital Status | Married, % (n) | 70.0 (7) | 66.7 (14) |
| Divorced, % (n) | 20.0 (2) | 14.3 (3) | |
| Single, % (n) | 10.0 (1) | 14.3 (3) | |
| Widowed, % (n) | 0 | 4.8 (1) | |
| Employment Status | Currently employed outside home, % (n) | 30.0 (3) | 28.6 (6) |
| Self-employed, % (n) | 0 | 9.5 (2) | |
| Retired, % (n) | 40.0 (4) | 19.0 (4) | |
| Disability, % (n) | 10.0 (1) | 14.3 (3) | |
| Homemaker, % (n) | 20.0 (2) | 19.0 (4) | |
| Not Working—Other, % (n) | 0 | 9.5 (2) | |
| BMI at Study Baseline | Mean, Kilograms/m2 (SD) | 28.4 (4.4) | 30.2 (7.2) |
| Age at First Breast Cancer Diagnosis | Mean (SD) | 52.9 (11.7) | 49.4 (10.9) |
| Years Elapsed Since First Diagnosis | Mean (SD) | 11.2 (7.9) | 9.7 (6.4) |
| Years Elapsed Since Diagnosis of Metastatic Breast Cancer | Mean (SD) | 5.3 (6.0) | 2.2 (1.8) |
| Hormone Receptor Status | ER + , % (n) | 100.0 (10) | 95.2 (20) |
| PR + , % (n) | 90.0 (9) | 81.0 (17) | |
| HER2 + , % (n) | 30.0 (3) | 28.6 (6) | |
| Location of Metastases | Bone, % (n) | 70.0 (7) | 90.5 (19) |
| Lung, % (n) | 40.0 (4) | 38.1 (8) | |
| Brain, % (n) | 10.0 (1) | 14.3 (3) | |
| Liver, % (n) | 20.0 (2) | 4.8 (1) | |
| Other, % (n) | 60.0 (6) | 33.3 (7) | |
| Cancer Therapy | Palbociclib, % (n) | 30.0 (3) | 47.6 (10) |
| Abemaciclib, % (n) | 10.0 (1) | 9.5 (2) | |
| Ribociclib, % (n) | 0 | 4.8 (1) | |
| Trastuzumab, % (n) | 20.0 (2) | 23.8 (5) | |
| Pertuzumab, % (n) | 10.0 (1) | 19.0 (4) | |
| Capecitabine, % (n) | 10.0 (1) | 4.8 (1) | |
| Letrozole, % (n) | 30.0 (3) | 61.9 (13) | |
| Anastrozole, % (n) | 30.0 (3) | 4.8 (1) | |
| Exemestane, % (n) | 10.0 (1) | 9.5 (2) | |
| Fulvestrant, % (n) | 20.0 (2) | 14.3 (3) | |
| Denosumab, % (n) | 10.0 (1) | 47.6 (10) | |
| Zoledronic acid, % (n) | 0 | 4.8 (1) | |
| Leuprolide, % (n) | 0 | 9.5 (2) |